Phage therapy: An alternative to antibiotics?

David Hegarty*

Department of Colorectal, Penn University, USA

Introduction

Phage therapy, a century-old concept, is experiencing a resurgence as the medical community grapples with the escalating problem of antibiotic resistance. Bacteriophages, or phages, are viruses that specifically infect and lyse bacteria. Discovered in the early 20th century by Frederick Twort and Félix d'Hérelle, phages were initially explored for their therapeutic potential. However, with the advent of antibiotics in the 1940s, interest in phage therapy waned. Today, as the efficacy of antibiotics diminishes and multidrug-resistant bacteria become more prevalent, phage therapy is being reconsidered as a viable alternative or complement to conventional antibiotics [1, 2].

One of the most significant advantages of phage therapy is its potential to target antibiotic-resistant bacteria. As antibiotic resistance becomes an increasingly critical global health issue, the need for alternative treatments is urgent. Phages offer a promising solution because their mode of action is entirely different from that of antibiotics. Bacteria that are resistant to antibiotics may still be susceptible to phages. Furthermore, phages can evolve alongside bacteria. When bacteria develop resistance to a particular phage, new phage variants can be selected to overcome this resistance, offering a dynamic and adaptive treatment strategy [3, 4].

Clinical applications of phage therapy have been explored in various contexts, with encouraging results. For instance, phage therapy has been used to treat chronic infections, such as those caused by Pseudomonas aeruginosa in cystic fibrosis patients, with some success. In these cases, phages have been able to penetrate biofilms – structured communities of bacteria that are notoriously difficult to eradicate with antibiotics. Phages' ability to disrupt biofilms represents a significant therapeutic advantage, as biofilm-associated infections are common in chronic wounds, medical device infections, and certain lung infections [5, 6].

Despite its potential, the application of phage therapy is not without challenges. One of the primary obstacles is the regulatory framework governing phage use. Unlike antibiotics, which are standardized chemical compounds, phages are biological entities that can vary widely. The specificity of phages means that a cocktail of different phages may be needed to effectively treat an infection, complicating the regulatory approval process. Moreover, each phage preparation must be tailored to the individual patient's bacterial infection, which raises issues of scalability and consistency in treatment [7, 8].

Additionally, the lack of robust clinical trials poses a barrier to widespread adoption of phage therapy. While there are numerous case reports and small-scale studies demonstrating the efficacy of phages, large-scale, randomized controlled trials are necessary to establish standardized protocols and determine the safety and efficacy of phage therapy across different types of infections and patient populations. Efforts are underway to conduct such trials, and early results are promising, but more data is needed to convince regulatory bodies and the medical community of the viability of phage therapy as a mainstream treatment option [9, 10].

Conclusion

Phage therapy offers a promising alternative to traditional antibiotics, particularly in the face of rising antibiotic resistance. Its unique mode of action, specificity, and ability to evolve alongside bacteria make it a powerful tool in the fight against bacterial infections. While significant challenges remain in terms of regulation, production, and clinical validation, ongoing research and technological advancements are paving the way for phage therapy to become an integral part of modern medicine. As the medical community continues to explore and refine this approach, phage therapy has the potential to revolutionize the treatment of bacterial infections and contribute to a more sustainable future in antimicrobial therapy.

References

1. Uyttebroek S, Chen B, Onsea J, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022;22(8):e208-20.
2. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int J Antimicrob Agents. 2019;53(1):16-21.
3. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):10-128.
4. Usman SS, Uba AI, Christina E. Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics. Mol Biol Rep. 2023;50(8):7055-67.
5. Chegini Z, Khoshbayan A, Taati Moghadam M, et al. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Annals of clinical microbiology and antimicrobials. 2020;19:1-7.

***Correspondence to:** David Hegarty**,** Department of Colorectal, Penn University, USA. E-mail: dhegart3@cp.edu

***Received:** 26-Feb-2024, Manuscript No. AAJIDMM-24-142971; **Editor assigned:** 28- Feb -2024, PreQC No. AAJIDMM-24-142971 (PQ); **Reviewed:** 13-Mar-2024, QC No. AAJIDMM-24-142971; **Revised:** 15- Mar-2024, Manuscript No. AAJIDMM-24-142971(R); **Published:** 20- Mar-2024, DOI:10.35841/aajidmm-8.2.196*

***Citation:** Hegarty D. Phage therapy: An alternative to antibiotics?. J Infect Dis Med Microbiol. 2024;8(2):196.*

6. Su ZT, Zenilman JM, Sfanos KS, et al. Management of chronic bacterial prostatitis. Curr Urol Rep. 2020;21:1-8.
7. Santacroce L, Di Domenico M, Montagnani M, et al. Antibiotic resistance and microbiota response. Curr Pharm Des. 2023;29(5):356-64.
8. Oromí-Bosch A, Antani JD, Turner PE. Developing phage therapy that overcomes the evolution of bacterial resistance. Annu Rev Virol. 2023;10:503-24.
9. Aranaga C, Pantoja LD, Martínez EA, et al. Phage therapy in the era of multidrug resistance in bacteria: a systematic review. Int J Mol Sci. 2022;23(9):4577.
10. Sousa C, Ferreira R, Azevedo NF, et al. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol. 2022;48(3):376-96.

Citation: *Hegarty D. Phage therapy: An alternative to antibiotics?. J Infect Dis Med Microbiol. 2024;8(2):196.*